Earnings Call Summary | ANI Pharmaceuticals(ANIP.US) Q1 2024 Earnings Conference
Earnings Call Summary | ANI Pharmaceuticals(ANIP.US) Q1 2024 Earnings Conference
The following is a summary of the ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript:
以下是ANI製藥公司（ANIP）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
ANI Pharmaceuticals reported Q1 revenues of $137.4 million, showing a 29% increase over Q1 2023.
EBITDA and EPS increased by 14% and 3% respectively.
Record revenues were reported from the company's Cortrophin Gel, marking a 126% YoY increase.
Generics business contributed $70.2 million in revenue, a 10% YoY increase.
Unrestricted cash at end of Q1 stood at $228.6 million, with the company's debt valued at $293.3 million, due in Nov 2027.
ANI Pharmicals公佈的第一季度收入爲1.374億美元，比2023年第一季度增長29％。
息稅折舊攤銷前利潤和每股收益分別增長了14％和3％。
該公司的Cortrophin Gel報告了創紀錄的收入，同比增長了126％。
仿製藥業務貢獻了7,020萬美元的收入，同比增長10％。
第一季度末的非限制性現金爲2.286億美元，該公司的債務價值爲2.933億美元，將於2027年11月到期。
Business Progress:
業務進展：
Cortrophin Gel showed strong commercial performance with continued growth in Q1 2024.
A new 1-mL vial of Cortrophin Gel for acute gouty arthritis flares was launched, expanding the Cortrophin franchise.
Six new products emerged from the generics business in Q1, securing their position as a top manufacturer.
ANI is actively evaluating M&A and in-licensing targets for further growth.
ANI reiterated their total company guidance of $520 million to $542 million in revenues, out of which Cortrophin Gel is expected to contribute $170 million to $180 million.
Anticipates high single-digit to low double-digit growth in generics in 2024.
Cortrophin Gel 顯示出強勁的商業表現，並在 2024 年第一季度持續增長。
一瓶新的1毫升的Cortrophin凝膠上市，用於急性痛風性關節炎的發作，擴大了Cortrophin的特許經營範圍。
第一季度仿製藥業務出現了六種新產品，鞏固了其作爲頂級製造商的地位。
ANI正在積極評估併購和許可目標，以實現進一步增長。
ANI重申了公司預期的總收入爲5.2億至5.42億美元，其中Cortrophin Gel預計將貢獻1.7億至1.8億美元。
預計2024年仿製藥的個位數至低兩位數的高增長。
More details: ANI Pharmaceuticals IR
更多詳情： ANI 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。